+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Microbiome Sequencing Market

  • ID: 4775834
  • Report
  • Region: Global
  • 148 Pages
  • BCC Research
1 of 5

FEATURED COMPANIES

  • Allele Pty Ltd.
  • Clinical Microbiomics A/S
  • Groken Bioscience Ltd.
  • Microbiome Insights Inc.
  • Qiagen N.V.
  • Starseq Gmbh
  • MORE

Report Scope:

This report provides an elaborate summary of the market, including a market snapshot and company profiles of key players competing in the microbiome sequencing market. It provides an exhaustive segmentation of the market with in-depth information about each segment. The overview section of the report provides a source of the description of market trends and market dynamics, which includes drivers, limitations, challenges, and opportunities in the market. It provides information about market development and future trends that can be useful for organizations, including wholesalers and exporters.

It provides market positioning of key players using the yardsticks of revenue, product portfolio, and recent activities. It includes strategies adopted by emerging market players with strategic recommendations for new market entrants. Outright information is provided in the report, consisting of historical and current market size and including the future potential of the market. The report will enable market players and new entrants to make an informed decision about the production and export of goods and services to the original equipment manufacturer.

The market is segmented on the basis of sequencing technology, component, applications, laboratory type, and end use. Geographic market analysis is provided for all major segments. The report offers a country-level analysis of the market to provide a better understanding of major segments.

Report Includes:

  • 60 data tables and 17 additional tables
  • An overview of the global market and technologies for genome sequencing within the industry
  • Analyses of global market size and trends, with data from 2017, 2018 and projections of CAGRs through 2023
  • Key outline of present and future market potentials, and factors influencing the microbiome sequencing market
  • Discussion on the impact of genome sequencing on pharmaceutical, biotechnology and healthcare sectors
  • Information on automated instruments and discussion on how it facilitates speedy sequencing procedures
  • Insights into government initiatives and funding for the development of effective drugs for the treatment and prevention from chronic diseases
  • Company profiles of the major players of the market, including Biolog Inc., CosmosID Inc., Illumina Inc., Metabiomics and Oxford Nanopore Technologies Ltd.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allele Pty Ltd.
  • Clinical Microbiomics A/S
  • Groken Bioscience Ltd.
  • Microbiome Insights Inc.
  • Qiagen N.V.
  • Starseq Gmbh
  • MORE

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst’s Credentials
  • Custom Research
  • Related Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • Market Trends
  • North America Dominates the Microbiome Sequencing Market
  • High-throughput Sequencing: Microbiome Research
  • Automated Instruments
  • AI and Virtual Simulation
  • Novel Technologies
  • Stem Cell Technologies
  • Market Dynamics
  • Key Factors Driving Market Growth

Chapter 4 Market Breakdown by Sequencing Technology

  • Sanger Sequencing
  • High-throughput Sequencing
  • Sequencing by Synthesis (SBS)
  • Sequencing by Ligation (SBL)
  • Shotgun Sequencing
  • Targeted Gene Sequencing (TGS)
  • RNA Sequencing
  • Whole Genome Sequencing (WGS)
  • Others (Methyl Sequencing)
  • Third-generation Sequencing

Chapter 5 Market Breakdown by Component

  • Reagents and Kits
  • Instruments
  • Liquid Handling Instruments
  • Cytometers
  • Imaging Devices
  • Microplate Reader

Chapter 6 Market Breakdown by Application

  • Drug Discovery
  • Genetic Screening
  • Disease Diagnosis Research
  • Personalized Medicine
  • Others (Therapeutics)

Chapter 7 Market Breakdown by End User

  • Pharmaceutical and Biotechnology
  • Academic Centers and Research Institutes
  • Contract Research Organizations (CROs)
  • Others (Nutritional)

Chapter 8 Market Breakdown by Laboratory Type

  • Dry Labs
  • Wet Labs

Chapter 9 Market Breakdown by Region

  • North America
  • The U.S.
  • Canada
  • Latin America
  • MEA
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • India
  • China
  • Japan
  • Rest of Asia-Pacific

Chapter 10 Patent Review/ New Developments

  • New Developments
  • Patent Analysis

Chapter 11 Analysis of Market Opportunities

  • Key Suppliers and Manufacturers Positioning and Strategy
  • Thermo Fisher Scientific Inc.
  • Illumina Inc.
  • Qiagen NV
  • Molzym GmbH & Co. KG
  • Novogene Corp.

Chapter 12 Company Profiles

  • Allele Pty Ltd.
  • Baseclear Bv
  • BGI
  • Biolog Inc.
  • Biomathematica
  • Biospherex Llc
  • Charles River Laboratories International Inc.
  • Clinical Microbiomics A/S
  • Corebiome Inc.
  • Cosmosid Inc.
  • Diversigen Inc.
  • Eurofins Group
  • Genome7
  • Groken Bioscience Ltd.
  • Human Longevity Inc.
  • Illumina Inc.
  • Labcyte Inc.
  • Leucine Rich Bio Pvt. Ltd.
  • Meghagen Biosciences Pvt. Ltd.
  • Metabiomics
  • Metagenom Bio Inc.
  • Microbiome Insights Inc.
  • Thermo Fisher Scientific Inc.
  • Microbiome Therapeutics Llc
  • Molzym Gmbh & Co. Kg
  • Norgenbiotek Corp.
  • Novogene Corp.
  • Oxford Nanopore Technologies Ltd.
  • Pacific Biosciences Of California Inc.
  • Phase Genomics Inc.
  • Pillar Biosciences Inc.
  • Qiagen N.V.
  • Rancho Biosciences Llc
  • Resphera Biosciences, Llc
  • Readcoor Inc.
  • Ritter Pharmaceuticals Inc.
  • Second Genome Inc.
  • Shoreline Biome, Llc.
  • Starseq Gmbh
  • Synlogic
  • Ubiome Inc.
  • Vaiomer
  • Viome Inc.
  • Zymo Research Corp.

List of Tables
Summary Table: Global Market for Microbiome Sequencing, by Sequencing Technology, Through 2023
Table 1: Cost Per Genome, 2001-2017
Table 2: Global Market for Microbiome Sequencing, by Sequencing Technology, Through 2023
Table 3: Sanger Sequencing vs. Targeted NGS
Table 4: Global Market for Sanger Sequencing, by Region, Through 2023
Table 5: Different NGS Technologies
Table 6: Experimental High-throughput Sequencing Technology
Table 7: Global Market for High-throughput Sequencing, by Region, Through 2023
Table 8: Global Market for High-throughput Sequencing, by Type, Through 2023
Table 9: Two-Channel SBS Instruments: Illumina Inc.
Table 10: Selected Hybridization Systems: Sequencing Technology
Table 11: Amplicon Sequencing vs. Target Enrichment
Table 12: First Generation, Second Generation and Third Generation Sequencing
Table 13: Global Market for Third-generation Sequencing, by Region, Through 2023
Table 14: Global Market for Microbiome Sequencing, by Component, Through 2023
Table 15: Global Market for Reagents and Kits Used in Microbiome Sequencing, by Region, Through 2023
Table 16: Global Market for Instruments Used in Microbiome Sequencing, by Region, Through 2023
Table 17: Global Market for Instruments Used in Microbiome Sequencing, by Type, Through 2023
Table 18: Global Market for Microbiome Sequencing, by Application, Through 2023
Table 19: Global Market for Microbiome Sequencing in Drug Discovery, by Region, Through 2023
Table 20: Global Market for Microbiome Sequencing in Genetic Screening, by Region, Through 2023
Table 21: Global Market for Microbiome Sequencing in Disease Diagnosis Research, by Region, Through 2023
Table 22: Global Market for Microbiome Sequencing in Personalized Medicine, by Region, Through 2023
Table 23: Global Market for Microbiome Sequencing in Others Application, by Region, Through 2023
Table 24: Global Market for Microbiome Sequencing, by End User, Through 2023
Table 25: Selected Biotech/Pharma Company Partnerships: Microbiome Projects
Table 26: Global Market for Microbiome Sequencing in Pharmaceutical and Biotechnology, by Region, Through 2023
Table 27: Important Events in NHGRI History, 1990-2016
Table 28: Academic Centers and Research Institutes Engaged in Microbiome Research
Table 29: Global Market for Microbiome Sequencing in Academic Centers and Research Institutes, by Region, Through 2023
Table 30: Global Market for Microbiome Sequencing in CROs, by Region, Through 2023
Table 31: Global Market for Microbiome Sequencing in Other End User Segments, by Region, Through 2023
Table 32: Global Market for Microbiome Sequencing, by Laboratory Type, Through 2023
Table 33: Global Market for Microbiome Sequencing Used in Dry Labs, by Region, Through 2023
Table 34: Global Market for Microbiome Sequencing Used in Wet Labs, by Region, Through 2023
Table 35: Global Market for Microbiome Sequencing, by Region, Through 2023
Table 36: North American Market for Microbiome Sequencing, by Country, Through 2023
Table 37: North American Market for Microbiome Sequencing, by Sequencing Technology, Through 2023
Table 38: North American Market for Microbiome Sequencing, by Component, Through 2023
Table 39: North American Market for Microbiome Sequencing, by Application, Through 2023
Table 40: North American Market for Microbiome Sequencing, by End User, Through 2023
Table 41: North American Market for Microbiome Sequencing, by Laboratory Type, Through 2023
Table 42: Microbiome Research Target Areas
Table 43: Cancer Statistics, 2017
Table 44: Microbes Designated as Class 1 (Carcinogens), by the IARC
Table 45: Colorectal Cancer Mortality Rate, 2011-2015
Table 46: Latin American Market for Microbiome Sequencing, by Sequencing Technology, Through 2023
Table 47: Latin American Market for Microbiome Sequencing, by Component, Through 2023
Table 48: Latin American Market for Microbiome Sequencing, by Application, Through 2023
Table 49: Latin American Market for Microbiome Sequencing, by End User, Through 2023
Table 50: Latin American Market for Microbiome Sequencing, by Laboratory Type, Through 2023
Table 51: MEA Market for Microbiome Sequencing, by Sequencing Technology, Through 2023
Table 52: MEA Market for Microbiome Sequencing, by Component, Through 2023
Table 53: MEA Market for Microbiome Sequencing, by Application, Through 2023
Table 54: MEA Market for Microbiome Sequencing, by End User, Through 2023
Table 55: MEA Market for Microbiome Sequencing, by Laboratory Type, Through 2023
Table 56: Major Microbiome Research Projects Across Europe, 2017-2018
Table 57: European Market for Microbiome Sequencing, by Country/Region, Through 2023
Table 58: European Market for Microbiome Sequencing, by Sequencing Technology, Through 2023
Table 59: European Market for Microbiome Sequencing, by Component, Through 2023
Table 60: European Market for Microbiome Sequencing, by Application, Through 2023
Table 61: European Market for Microbiome Sequencing, by End User, Through 2023
Table 62: European Market for Microbiome Sequencing, by Laboratory Type, Through 2023
Table 63: Expenditures on Research: Crohn’s Disease and Ulcerative Colitis, 2009-2014
Table 64: Relation of Microbiomes in Advancement of Numerous Diseases
Table 65: Asia-Pacific Market for Microbiome Sequencing, by Sequencing Technology, Through 2023
Table 66: Asia-Pacific Market for Microbiome Sequencing, by Component, Through 2023
Table 67: Asia-Pacific Market for Microbiome Sequencing, by Application, Through 2023
Table 68: Asia-Pacific Market for Microbiome Sequencing, by End User, Through 2023
Table 69: Asia-Pacific Microbiome Sequencing, by Laboratory Type, Through 2023
Table 70: Asia-Pacific Market for Microbiome Sequencing, by Country/Region, Through 2023
Table 71: Leading Types of Cancer in Hong Kong, 2005 and 2015
Table 72: Selected Developments in Microbiome Sequencing
Table 73: Number of Patents for Microbiome Sequencing, by Country/Region, 2016-2019
Table 74: Number of Patents on Microbiome Sequencing, by Organization, 2016-2018
Table 75: Patents on Microbiome Sequencing, 2016-2019
Table 76: Distributors

List of Figures
Summary Figure: Global Market for Microbiome Sequencing, by Sequencing Technology, 2017-2023
Figure 1: Business Collaboration Benefits
Figure 2: Personalized Medicines Approved by the U.S. FDA, 2014-2017
Figure 3: Expansion of Human Microbiome Research at NIH, 2012-2016
Figure 4: Canadian Cancer Facts, 2017
Figure 5: Prevalence of Diabetes in MEA, by Gender, 2017
Figure 6: Healthcare Spending in Germany, 2013-2016
Figure 7: Mortality Rate: Colorectal Cancer in Germany, by Gender, 2011-2015
Figure 8: Mortality from Cancer UK, 2011-2017
Figure 9: Colorectal Cancer in France, 2014-2016
Figure 10: Incidence of CVD in France, by Gender, 2010 and 2015
Figure 11: Colorectal Cancer in Italy, 2015 and 2016
Figure 12: Prevalence of CVD in Italy, 2010 and 2015
Figure 13: HIV in Spain, 2016
Figure 14: Prevalence of CVD in Rest of European Countries, 2010 and 2015
Figure 15: Global Burden Disease Database
Figure 16: Top Five Cancer Types in Japan, 2017
Figure 17: Thermo Fisher Scientific Inc.: Revenue, by Complementary Segment, 2017
Figure 18: Thermo Fisher Scientific Inc.: Revenue, by Region, 2017
Figure 19: Illumina Inc.: Revenue, by Complementary Segment, 2017
Figure 20: Illumina Inc.: Revenue, by Region, 2017
Figure 21: Qiagen NV: Revenue, by Complementary Segment, 2017
Figure 22: Qiagen NV: Revenue, by Region, 2017

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Allele Pty Ltd.
  • Clinical Microbiomics A/S
  • Groken Bioscience Ltd.
  • Microbiome Insights Inc.
  • Qiagen N.V.
  • Starseq Gmbh
  • MORE

Researchers from around the globe find significant potential in microbiome study to explore gut-related, metabolic, inflammatory, auto-immune diseases, neurological conditions and more. Microbiome sequencing is one key process used in the analysis of human microbiomes. Innovative sequencing technologies such as NGS and Third-generation Sequencing generate data on the human microbiome. Novel High-throughput Sequencing via hardware and software tools are revolutionizing microbiome sequencing. These technologies enable the delivery of services at high speed, with good quality, and at an attractive cost. The global microbiome sequencing market is expected to witness significant growth during the forecast period (2018-2023).

The microbiome sequencing market is driven by numerous factors including an increasing emphasis on microbiome sequencing for early detection and diagnosis. Many market players are engaging in collaborative AI (Artificial Intelligence) for microbiome sequencing to promote studies on gut microbiomes. In 2018, Viome Inc. developed Vie’s AI system. The system uses data gathered from four sources: biological testing, expert knowledge, customer feedback, and scientific literature. Increased government spending for the promotion of microbiome research is expected to promote the growth of the global market in the future. One such initiative is the Human Microbiome Project (HMP), which began in 2007 as an extension of the Human Genome Project. The project, put forth by the NIH, was initiated to enhance research on microbiomes in the U.S. The cost associated with sequencing technologies has decreased over the past few years.

Microbiome sequencing technology has numerous applications. Companies such as Metagenom Bio Inc. and Resphera Biosciences LLC provide microbiome products and services in various sectors: agriculture, mining, computational and bioproducts. Since microbiome sequencing is a new technology, a lack of skilled labor is one factor expected to have a negative impact on the growth of the market.

The global microbiome sequencing market has been segmented on the basis of sequencing technology, components, applications, end users and laboratory types. The global microbiome sequencing market has been segmented into technologies: Sanger Sequencing, High-throughput Sequencing, and Third Generation Sequencing. Sanger Sequencing is the dominant technology in the microbiome sequencing market. Sanger Sequencing is preferred by biologists and researchers due to its accuracy. It offers new perspectives for genome analysis and exploration and is based on the chain termination method.

Note: Product cover images may vary from those shown
5 of 5
  • Allele Pty Ltd.
  • Baseclear Bv
  • BGI
  • Biolog Inc.
  • Biomathematica
  • Biospherex Llc
  • Charles River Laboratories International Inc.
  • Clinical Microbiomics A/S
  • Corebiome Inc.
  • Cosmosid Inc.
  • Diversigen Inc.
  • Eurofins Group
  • Genome7
  • Groken Bioscience Ltd.
  • Human Longevity Inc.
  • Illumina Inc.
  • Labcyte Inc.
  • Leucine Rich Bio Pvt. Ltd.
  • Meghagen Biosciences Pvt. Ltd.
  • Metabiomics
  • Metagenom Bio Inc.
  • Microbiome Insights Inc.
  • Microbiome Therapeutics Llc
  • Molzym Gmbh & Co. Kg
  • Norgenbiotek Corp.
  • Novogene Corp.
  • Oxford Nanopore Technologies Ltd.
  • Pacific Biosciences Of California Inc.
  • Phase Genomics Inc.
  • Pillar Biosciences Inc.
  • Qiagen N.V.
  • Rancho Biosciences Llc
  • Readcoor Inc.
  • Resphera Biosciences, Llc
  • Ritter Pharmaceuticals Inc.
  • Second Genome Inc.
  • Shoreline Biome, Llc.
  • Starseq Gmbh
  • Synlogic
  • Thermo Fisher Scientific Inc.
  • Ubiome Inc.
  • Vaiomer
  • Viome Inc.
  • Zymo Research Corp.
Note: Product cover images may vary from those shown
Adroll
adroll